COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

202302_USP_797-2-1768x923.jpg

by Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services

If you missed Part 1 of USP 797: Revisions & Impacts, it can be found here.

ENVIRONMENTAL MONITORING

Personnel compounding Category 3 sterile preparations are required to perform media fills with glove fingertip sampling and surface sampling of the direct compounding area at least every three months, compared to at least every six months for those compounding Category 1 or 2 sterile preparations.

Pharmacies compounding Category 3 sterile preparations also require more frequent monitoring. Thirty days prior to starting to compound any Category 3 batches, viable air sampling must be conducted. Viable air sampling using an impaction device must be completed for each classified area monthly for facilities preparing Category 3 sterile preparations, compared to every six months for facilities preparing Category 1 or 2 preparations.

Surface sampling is required weekly for Category 3 sterile preparations and must be performed in the ISO 5 with each batch of a Category 3 CSP unless using a self-enclosed robotic device. By contrast, for Category 1 or Category 2 preparations, surface sampling is required monthly. Surface sampling must be done in all classified areas and pass-throughs. The sampling must include:

  • Each classified area, including each room

  • The interior of each ISO Class 5 primary engineering control (PEC)

  • Pass-through chambers connecting to classified areas

  • Equipment contained within the PEC

  • Staging or work area(s) near the PEC

  • Frequently touched surfaces

Pharmacies must also conduct viable air sampling and surface sampling:

  • When new facilities and equipment are certified

  • After servicing any facility or equipment (see Section 4, Facilities and Engineering Controls)

  • After identifying any problem (e.g., microbial growth in preparation sterility tests)

  • After identifying any problematic trends (e.g., failed fingertip/thumb sampling results, failed media-fill testing, or repeated air or surface contamination)

  • Any changes are made to the facility or processes that could impact the compounding environment (e.g., change in cleaning agents)

Pharmacies must also conduct total airborne particle-count testing in all classified areas during dynamic operating conditions at least every six months for all categories of sterile preparations.

CLEANING AND SANITIZING

Cleaning and sanitizing procedures also changed in Chapter 797 revisions. Pharmacies must clean surfaces prior to disinfecting them unless they use EPA-registered (or equivalent outside the U.S.) one-step disinfectant cleaners that simultaneously clean and disinfect with an appropriate contact time specified by the product.

In a PEC, after cleaning and disinfecting, pharmacies must apply sterile 70% isopropyl alcohol (IPA) to remove any residues of the product(s). Sterile 70% IPA must also be applied immediately before initiating compounding.

Another significant difference exists in the frequency of sporicidal application between Categories 1 and 2 and Category 3 preparations. When pharmacies create Category 3 preparations, they must apply a sporicidal agent to the PEC, including the removable work tray (if applicable), the equipment and work surfaces outside the PEC (pass-throughs and floors) at least weekly. Compounding Categories 1 and 2 preparations require monthly application of a sporicidal agent to all areas.

Along with these changes, the process for cleaning and disinfecting the PEC received more detailed directions. Compounders must:

  • If necessary, remove visible particles, debris or residue with an appropriate solution (e.g., Sterile Water for Injection or Sterile Water for Irrigation) using sterile, low-lint wipers.

  • Use a sterile low-lint wiper, apply a sterile cleaning agent followed by a sterile EPA-registered disinfectant, or apply a sterile EPA-registered (or equivalent for entities outside the U.S.) one-step disinfectant cleaner to equipment and all PEC interior surfaces.

  • Ensure the contact time specified by the manufacturer is achieved.

  • Use a sterile low-lint wiper, apply sterile 70% IPA to equipment and all PEC interior surfaces.

  • Allow the surface to dry completely before beginning compounding.

WHAT COMES NEXT

USP 795 and 797 are official and possibly enforceable in your state on November 1, 2023. Revisions to USP 795 and 797 also make USP Chapter 800, Hazardous Drugs — Handling in Healthcare Settings, “compendially applicable” (USP term) and possibly enforceable in many states on November 1, 2023. For more information on Chapter 800, visit pccarx/USP Update/800.

PCCA offers resources to help pharmacies navigate the changing compounding standards and regulatory environment, including our blog on FDA Insanitary Conditions and limited USP training courses at eLearning Compounding Training. 

PCCA offers additional resources to our members, including all courses offered in our eLearning Compounding Training, multiple online webinars and training sessions and, for members with Clinical Services, Speakers Bureau to guide, assist and educate compounding pharmacy staff. Members with Clinical Services may also contact our Clinical Services team for help with formulas and other compounding concerns.


The complete version of this article originally appeared in PCCA’s members-only magazine, the Apothagram.



Comments are closed.